neuroendocrine tumor

Jim, what are neuroendocrine disorders and how does this new approval help patients with this rare condition?

The approval is for a generic version of Novartis' radioligand therapy, Mudifera, to treat neuroendocrine tumors.

The approval is largely based on showing the new generic drug, Ravnesta, had similar bio and therapeutic equivalents.

Neuroendocrine tumors are slow growing cancers.

This approval is for a subset of those tumors that mainly impact the GI and pancreas.

Like most GI and pancreatic mediated disease, this one is hard to define, hard to measure, and hard to treat.

Orphan drugs can tend to be expensive because they're developed for small patient populations.

So affordability and access are important considerations when you come to this space.

GLP-1 medications have transformed the treatment of diabetes and obesity, and their use has exploded.

But for people living with neuroendocrine cancer, they've also raised an important question.

Are GLP-1 safe if you have neuroendocrine cancer? The answer isn't a simple yes or no.

Researchers have discovered that some neuroendocrine tumors express the GLP-1 receptor, the same receptor targeted by GLP-1 medications.

New studies of human tumor samples suggest that GLP-1 receptor expression varies considerably by tumor type.

At the same time, GLP-1s can provide significant health benefits.

And for people with cancer who take them, there's another consideration, how weight loss, decreased appetite, and potential muscle loss could affect nutrition, strength, and treatment.

I'm Jessica Thomas, Director of Patient Education at NetRF, and you're listening to NetWise, the podcast designed to inform, empower, and guide patients and caregivers through the world of neuroendocrine cancer.

GLP-1 medications have transformed the treatment of diabetes and obesity, and their use has exploded.

But for people living with neuroendocrine cancer, they've also raised an important question.

Are GLP-1 safe if you have neuroendocrine cancer? The answer isn't a simple yes or no.

Researchers have discovered that some neuroendocrine tumors express the GLP-1 receptor, the same receptor targeted by GLP-1 medications.

New studies of human tumor samples suggest that GLP-1 receptor expression varies considerably by tumor type.

At the same time, GLP-1s can provide significant health benefits.

And for people with cancer who take them, there's another consideration, how weight loss, decreased appetite, and potential muscle loss could affect nutrition, strength, and treatment.

I'm Jessica Thomas, Director of Patient Education at NetRF, and you're listening to NetWise, the podcast designed to inform, empower, and guide patients and caregivers through the world of neuroendocrine cancer.